Albemarle R&D decreased by 24.7% to $9.17M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 35.0%, from $14.10M to $9.17M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a -1.2% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.98M | $13.29M | $12.13M | $16.08M | $17.39M | $18.36M | $20.15M | $20.47M | $21.42M | $21.08M | $22.75M | $23.53M | $20.77M | $22.40M | $20.02M | $14.10M | $12.44M | $12.67M | $12.18M | $9.17M |
| QoQ Change | — | -4.9% | -8.8% | +32.6% | +8.1% | +5.6% | +9.8% | +1.6% | +4.6% | -1.6% | +7.9% | +3.4% | -11.7% | +7.8% | -10.6% | -29.6% | -11.7% | +1.8% | -3.9% | -24.7% |
| YoY Change | — | — | — | — | +24.4% | +38.1% | +66.2% | +27.3% | +23.2% | +14.8% | +12.9% | +15.0% | -3.0% | +6.2% | -12.0% | -40.1% | -40.1% | -43.4% | -39.2% | -35.0% |
Range$9.17M – $23.53M
CAGR-8.5%
Avg YoY Growth+1.0%
Median YoY Growth+9.6%
Current Streak2 quarters decline
R&D at Other Companies
Frequently Asked Questions
- What is Albemarle's r&d?
- Albemarle (ALB) reported r&d of $9.17M in Q1 2026.
- How has Albemarle's r&d changed year-over-year?
- Albemarle's r&d decreased by 35.0% year-over-year, from $14.10M to $9.17M.
- What is the long-term trend for Albemarle's r&d?
- Over 4 years (2021 to 2025), Albemarle's r&d has grown at a -1.2% compound annual growth rate (CAGR), from $54.03M to $51.40M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.